Nombre del producto:(R)-4-(2,4-dimethoxybenzyl)-3-methylpiperazin-2-one

IUPAC Name:(3R)-4-[(2,4-dimethoxyphenyl)methyl]-3-methylpiperazin-2-one

CAS:1383146-20-0
Fórmula molecular:C14H20N2O3
Pureza:95%
Número de catálogo:CM131538
Peso molecular:264.33

Unidad de embalaje Stock disponible Precio($) Cantidad
CM131538-100mg in stock ȃƿ
CM131538-250mg in stock ŤǪǙ
CM131538-1g in stock Ǚƈƈ

Sólo para uso en I+D..

Formulario de consulta

   refresh    

Detalles del producto

Núm. De CAS :1383146-20-0
Fórmula molecular:C14H20N2O3
Punto de fusión:-
Código de sonrisas:O=C1NCCN(CC2=CC=C(OC)C=C2OC)[C@@H]1C
Densidad:
Número de catálogo:CM131538
Peso molecular:264.33
Punto de ebullición:436.1±45.0°C at 760 mmHg
Nº Mdl:MFCD22372628
Almacenamiento:Store at room temperature.

Category Infos

Piperazines
Piperazine is an organic compound consisting of a six-membered ring containing two nitrogen atoms in opposite positions in the ring. The chemical formula of piperazine is C4H10N2, and it is an important pharmaceutical intermediate. Pyrimidines and piperazines are known to be the backbone of many bulk compounds and important core structures for approved drugs; studies have shown that combining a pyridine ring with a piperazine moiety within a single structural framework enhances biological activity.

Column Infos

Fezolinetant
Dec 10, 2023, VEOZA (fezolinetant) approved by European Commission for treatment of vasomotor symptoms associated with menopause.
VEOZAH is the first and only neurokinin 3 (NK3) receptor antagonist that blocks NKB from binding on KNDy neurons to help reduce heat signals that trigger VMS. First-in-class fezolinetant brings women a new nonhormonal therapy for hot flashes.
In May 2023, FDA has approved VEOZA(fezolinetant) 45 mg once daily for the treatment of moderate to severe VMS due to menopause.

Related Products